Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Telix Pharma | Sydney | Salute | Ricerca medica e biotecnologica | 8,31 Mrd A$ | 163,7x | 0,85 | 24,84 A$ | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,4% Ribasso | Fai l’upgrade a Pro+ | |
Clarity Pharmaceuticals | Sydney | Salute | Ricerca medica e biotecnologica | 1,85 Mrd A$ | -44,3x | 0,77 | 5,59 A$ | -3,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 46,5% Rialzo | Fai l’upgrade a Pro+ | |
Mesoblast | Sydney | Salute | Ricerca medica e biotecnologica | 1,80 Mrd A$ | -11,4x | -0,98 | 1,59 A$ | -9,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -20,5% Ribasso | Fai l’upgrade a Pro+ | |
Opthea | Sydney | Salute | Ricerca medica e biotecnologica | 861,77 Mln A$ | -1,3x | 0,37 | 0,70 A$ | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21,5% Rialzo | Fai l’upgrade a Pro+ | |
PYC Therapeutics Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 787,63 Mln A$ | -17,6x | 0,65 | 1,69 A$ | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Immutep | Sydney | Salute | Ricerca medica e biotecnologica | 465,46 Mln A$ | -8,9x | -0,54 | 0,32 A$ | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Imugene Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 290,05 Mln A$ | -1,9x | 0,01 | 0,04 A$ | -8,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Orthocell Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 264,94 Mln A$ | -30,9x | 2,16 | 1,12 A$ | 9,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Race Oncology | Sydney | Salute | Ricerca medica e biotecnologica | 238,66 Mln A$ | -16,7x | 0,45 | 1,40 A$ | 9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Paradigm Biopharmaceuticals Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 202,67 Mln A$ | -2,9x | -0,82 | 0,58 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 47,4% Rialzo | Fai l’upgrade a Pro+ | |
Dimerix | Sydney | Salute | Ricerca medica e biotecnologica | 200,82 Mln A$ | -9,5x | -1,03 | 0,36 A$ | -2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Arovella Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 199,17 Mln A$ | -20,9x | -0,65 | 0,19 A$ | 7,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
CogState Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 184,37 Mln A$ | 21,5x | 0,37 | 1,07 A$ | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 33% Rialzo | Fai l’upgrade a Pro+ | |
LTR Pharma | Sydney | Salute | Ricerca medica e biotecnologica | 166,11 Mln A$ | -34x | 0,04 | 1,06 A$ | -1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Avita Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 103,95 Mln A$ | -1,1x | 0,09 | 3,96 A$ | -4,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11,4% Rialzo | Fai l’upgrade a Pro+ | |
Argenica Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 89,66 Mln A$ | -15,1x | -0,88 | 0,67 A$ | -4,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Pacific Edge | Sydney | Salute | Ricerca medica e biotecnologica | 89,60 Mln A$ | -3,5x | -0,4 | 0,13 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Actinogen Medical | Sydney | Salute | Ricerca medica e biotecnologica | 88,35 Mln A$ | -5x | 11,74 | 0,03 A$ | -3,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Proteomics Intl Labs | Sydney | Salute | Ricerca medica e biotecnologica | 85,15 Mln A$ | -12,8x | -3,12 | 0,65 A$ | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -23,7% Ribasso | Fai l’upgrade a Pro+ | |
Percheron Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 75,26 Mln A$ | -5,1x | -0,32 | 0,07 A$ | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Neurotech Intl | Sydney | Salute | Ricerca medica e biotecnologica | 65,18 Mln A$ | -10,5x | -0,33 | 0,06 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Tryptamine Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 54,89 Mln A$ | -2,9x | -0,57 | 0,04 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Anteo Diagnostics | Sydney | Salute | Ricerca medica e biotecnologica | 45,30 Mln A$ | -4,3x | -0,15 | 0,02 A$ | -5,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
IDT Australia Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 42,98 Mln A$ | -6,3x | -0,15 | 0,10 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bioxyne Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 40,93 Mln A$ | -2,9x | 0,01 | 0,02 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cynata Therapeutics Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 38,85 Mln A$ | -4x | -0,09 | 0,22 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Clever Culture Systems | Sydney | Salute | Ricerca medica e biotecnologica | 35,15 Mln A$ | -5x | -0,08 | 0,02 A$ | 17,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Prescient Therapeutics Ltd | Sydney | Salute | Ricerca medica e biotecnologica | 33,02 Mln A$ | -4,2x | 0,61 | 0,04 A$ | -2,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Noxopharm | Sydney | Salute | Ricerca medica e biotecnologica | 29,22 Mln A$ | -8,3x | -0,11 | 0,10 A$ | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alterity Therapeutics | Sydney | Salute | Ricerca medica e biotecnologica | 26,60 Mln A$ | -1x | -0,14 | 0,005 A$ | 25% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |